CCTV net news ( news broadcast ): malignant tumors are the biggest enemies of human health which are usually either poorly treated or cannot be treated. After ten years of research and development, a new drug that can " kill" tumor cells accurately was born and became the first original new drug authorized by our country to the United States and other developed countries. Its developer is Lu Xianping, the leading scientist in new drug research and development in our country. Lu Xianping said that what he wanted to do was not only a new drug, but also to make it a life-saving drug that people could afford.

Lu Xianping, 52, has been tackling key problems for ten years. Lu Xianping led the team to develop the first original chemical, Chidamide in China, which brings new hope to patients with malignant lymphoma.

The development and marketing of a new drug usually requires more than five years of clinical trials. Eight years ago, he won a battle against cancer when Chidamide was just used in clinic. That year, Shi Lei who is 66 years old was diagnosed with cell lymphoma. The number of initial and recurrent cases of this disease in our country is about 50,000 each year, and the five-year survival rate is only 25 %, while the diagnosis of Shi Lei has reached the advanced stage.

Cancer cells are still growing crazily. Just then, Chidamide developed by Lu Xianping entered the clinical stage.

When it comes to Chidamide's anti-cancer principle, it is necessary to mention a high molecular substance--enzymes. Almost all cell activities require the participation of enzymes. By precisely controlling the four enzymes closely related to the activity of tumor cells, Chidamide can activate the immune function of anti-tumor cells in the human body and control the recurrence and metastasis of tumors.

Chidamide played an extraordinary role in Shi Lei. After a period of treatment, he began to recover.

According to international practice, the research and development of a new drug takes about ten years on average and costs about one billion US dollars.

The development and marketing of a new drug usually require complicated clinical trials. After tens of thousands of experiments in 12 years, the first original chemical drug in China Chidamide was officially listed in March this year. The huge development cost has set the monthly treatment cost for this new drug at 26,000 yuan. Although it is only equivalent to 1/10 of the price of similar drugs in the United States, it is still out of reach for many patients from poor families.

In Shijiazhuang, Hebei province, a young man, who was in his prime, was diagnosed with late T-cell lymphoma when preparing for the college entrance examination two years ago, which dealt a heavy blow to the low-income families with only a few hundred yuan in income monthly.

At this time, in Shenzhen, Lu Xianping made a decision to treat 40 low-income patients free of charge every year, which means that the company will lose 12 million yuan of sales revenue every year. Investors strongly oppose it, but Lu Xianping has his own insistence.

Lu Xianping's decision has revived Yu Haoran, who is thousands of miles away and on the verge of life and death.

In the past, there were only a few new drugs created by China and recognized by the world. The successful research and development of Chidamide has also become the first original new drug authorized for patent use in developed countries such as the United States and Japan.